[Translation] A Phase I clinical study evaluating the safety, tolerability, and pharmacokinetics of HiD21 for injection in patients with advanced malignant tumors
评价注射用HID21在晚期肿瘤患者中的安全性和耐受性;确定注射用HID21治疗晚期肿瘤患者的最大耐受剂量(MTD)/推荐扩展剂量(RDE);初步评价注射用HID21的抗肿瘤活性;评价注射用HID21的药代动力学、药效学特征
[Translation] Evaluate the safety and tolerability of HID21 for injection in patients with advanced tumors; determine the maximum tolerated dose (MTD)/recommended dose expansion (RDE) of HID21 for injection in patients with advanced tumors; preliminarily evaluate the anti-tumor activity of HID21 for injection; and evaluate the pharmacokinetic and pharmacodynamic characteristics of HID21 for injection.